Assessing the real-world safety of fenofibric acid for hyperlipidemia: results from WHO-VigiAccess and FAERS databases
In addition to the known adverse reactions, this study has identified numerous potential adverse drug reactions associated with fenofibric acid. Although these findings require further validation through subsequent clinical trials, they provide valuable safety information for clinicians to consider when evaluating adverse effects in patients treated with fenofibric acid.
Authors
- Jie Zhang (ORCID: https://orcid.org/0000-0001-7821-4808)
- Yi Wang (ORCID: https://orcid.org/0000-0002-0818-724X)
- Xuepin Chen
- Zhiwen Yao (ORCID: https://orcid.org/0000-0001-6176-3720)
- Yaxing Li (ORCID: https://orcid.org/0000-0002-0586-1016)
- Ruonan Zhang (ORCID: https://orcid.org/0000-0002-6987-3606)
- Xingli Xu
Institutions
- Qingdao University (CN)
- Nanjing University of Chinese Medicine (CN)
- Shandong University of Traditional Chinese Medicine (CN)
- University of Electronic Science and Technology of China (CN)
- Shandong University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-11-07
- DOI
- https://doi.org/10.3389/fmed.2025.1702197
- Primary Topic
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation